Actively Recruiting
Open-Label Access Protocol for Patients Continuing Remibrutinib After Previous Novartis Studies in Dermatology or Allergy
Led by Novartis Pharmaceuticals · Updated on 2026-10-16
650
Participants Needed
43
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research focuses on participants who have completed a previous Novartis-sponsored study involving remibrutinib, a drug used in dermatological or allergology conditions. It aims to provide continued access to remibrutinib treatment and monitor long-term safety for up to three years, specifically for those benefiting from the treatment and unable to access it outside clinical trials. Participants will receive remibrutinib tablets at the dose and schedule they last followed in their earlier study. There is no screening period after consent and enrollment at the study site, treatment begins immediately. Participants will return to the study center at least every 16 weeks to receive their medication supply but may come back sooner if needed. Treatment can continue up to three years or until certain conditions such as loss of benefit, withdrawal, pregnancy, or other reasons arise. During the study, participants will have regular visits for medication resupply and monitoring. Researchers will track adverse events and serious adverse events throughout the study duration, approximately seven years, to assess long-term safety. Participation involves ongoing evaluation by the investigator to ensure benefits outweigh risks, with continuous access to treatment under medical supervision.
CONDITIONS
Brief Title
Remibrutinib Open Label Roll-over Post-trial Access Protocol
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here